Portal de Periódicos da CAPES

Efficacy of probiotics on the modulation of gut microbiota in the treatment of diabetic nephropathy

2022; Volume: 13; Issue: 3 Linguagem: Inglês

10.4239/wjd.v13.i3.150

1948-9358

Nozomi Nagase, Yuka Ikeda, Ai Tsuji, Yasuko Kitagishi, Satoru Matsuda,

Tryptophan and brain disorders

Diabetic nephropathy (DN) is a major cause of end-stage renal disease, and therapeutic options for preventing its progression are insufficient. The number of patients with DN has been increasing in Asian countries because of westernization of dietary lifestyle, which may be associated with the following changes in gut microbiota. Alterations in the gut microbiota composition can lead to an imbalanced gastrointestinal environment that promotes abnormal production of metabolites and/or inflammatory status. Functional microenvironments of the gut could be changed in the different stages of DN. In particular, altered levels of short chain fatty acids, D-amino acids, and reactive oxygen species biosynthesis in the gut have been shown to be relevant to the pathogenesis of the DN. So far, evidence suggests that the gut microbiota may play a key role in determining networks in the development of DN. Interventions directing the gut microbiota deserve further investigation as a new protective therapy in DN. In this review, we discuss the potential roles of the gut microbiota and future perspectives in the protection and/or treatment of kidneys.